Get started
Author

Viviane P. Sprecher

Observed names: Sprecher, Viviane Patricia, Viviane P Sprecher, Viviane Sprecher
ORCID: 0000-0002-1558-6687
Observed ORCID: 0000-0002-1558-6687
OpenAlex ID: A5089616833
Efficacy and Safety of Moxidectin-Albendazole and Ivermectin-Albendazole Combination Therapy Compared to Albendazole Monotherapy in Adolescents and Adults Infected with Trichuris trichiura: A Randomized, Controlled Superiority Trial
2023 · Viviane P Sprecher, Jean T Coulibaly, et al. · Clinical Infectious Diseases · 24
Evaluation of code‐based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databases
2020 · Viviane P. Sprecher, Eva‐Maria Didden, et al. · Pulmonary Circulation · 21
PDF
Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial
2023 · Viviane P Sprecher, Daniela Hofmann, et al. · The Lancet Infectious Diseases · 18
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a single-blind, randomised, controlled, dose-ranging, phase 2 trial
2025 · Viviane P Sprecher, Annina Schnoz, et al. · The Lancet Infectious Diseases · 3
PDF
Efficacy and safety of moxidectin–albendazole combination therapy for Trichuris trichiura infections in school-aged children: a double-blind, randomised, controlled, superiority trial
2025 · Annina Schnoz, Viviane P Sprecher, et al. · The Lancet Infectious Diseases · 3
PDF
Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d’Ivoire
2024 · Veshni Pillay-Fuentes Lorente, Jacinta N. Nwogu-Attah, et al. · Drugs in R&D · 2
PDF
Hybrid-metagenomics reveal off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria
2025 · Julian Dommann, Viviane P. Sprecher, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
Efficacy and Safety of Moxidectin-Albendazole and Ivermectin-Albendazole Combination Therapy Compared to Albendazole Monotherapy in Adolescents and Adults Infected with Trichuris trichiura: A Randomised Controlled Superiority Trial
2023 · Viviane Sprecher, Jean Coulibaly, et al. · SSRN Electronic Journal · 1
Combined high-quality metagenomics reveals off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria
2026 · Julian Dommann, Viviane P. Sprecher, et al. · npj Biofilms and Microbiomes
PDF
Efficacy and Safety of Ascending Doses of Ivermectin Co-Administered with Albendazole for Trichuris Trichiura Infections in Preschool-Aged Children: A Single-Blind Randomised Controlled Dose-Ranging Trial
2025 · Viviane Sprecher, Annina Schnoz, et al. · SSRN Electronic Journal
Pharmacometric Analysis to Describe Pharmacokinetics and Exposure‐Efficacy Response of Ivermectin in Adolescents Infected with Trichuris trichiura
2024 · David T. Ajayi, Ochuko M. Orherhe, et al. · The Journal of Clinical Pharmacology
PDF
Efficacy and Safety of Moxidectin Compared to Ivermectin Against Strongyloides Stercoralis Infection in Laotian and Cambodian Adults: A Randomised, Double-Blind, Non-Inferiority, Phase 2/3 Trial
2023 · Viviane Sprecher, Daniela Hofmann, et al. · SSRN Electronic Journal
Works count: 13
Citation count: 73
H-index: 3
I10-index: 3
Year
Topic
Type